Jubilant Pharmova is engaged in the development, manufacturing, and commercialization of pharmaceuticals including radiopharmaceuticals, allergy immunotherapy, generics, and contract research and development. The company also provides services for drug discovery and active pharmaceutical ingredients.

Jubilant Pharmova

Finance and Administration

Arun Sharma

Business Management

Azhagumarimuthu Thangamariappan

Bathuri venkat kumar

Associate Director - Logistics

Deepak Pancholi

Head Engineering

Dharmendrasinh Solanki

Director Sales (NSM)

kumar Deepak

Sales and Support

Manya Chopra

Namita Gautam

Associate Director -OD and Employee Engagement

Palak Singh

Director - Human Resources

Piyush Misra

Tushar Gupta

Chief of Operations

Head of Corporate Strategy

Shyam Bhartia

Founder & Chairman

Pharmaceutical Companies With Less Than $1B in Revenue (Top 10K)

Asia Health Care Companies (Top 10K)

Asia-Pacific (APAC) Pharmaceutical Companies

Pharmaceutical Companies With More Than $500 in Revenue

Jubilant Pharmova provides pharmaceuticals, drug discovery, and development solutions businesses.

Noida

Uttar Pradesh

India

Asia

Oil drops 4% in five days on record US crude output ahead of US elections, Fed verdict; Brent settles at $73/bbl

Jubilant Pharmova Q2 Results Live: Profit Rises by 64.48% YOY

India's Jubilant Pharmova posts bigger Q2 profit on strong demand

Jubilant Pharmova Limited Appoints Tushar Gupta as Chief of Operations

Jubilant Pharmova hits all time high on receiving 'VAI' tag for US facility

Jubilant Pharmova hits 52-week high after Q1 PAT zooms to Rs 482 cr

Jubilant Pharmova unit to prepay $75 mln term loan

India's Jubilant Pharmova reports narrower fourth-quarter loss

Jubilant Pharmova Q4 net profit jumps over two-fold to Rs 61 crore

India's Jubilant Pharmova posts quarterly profit

Jubilant Pharmova Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Pharmaceuticals; Contract Research & Development Services; and Proprietary Novel Drugs. The Pharmaceuticals segment engages in the manufacturing and supply of allergy therapy products, contract manufacturing of sterile injectables and non-sterile products, active pharmaceutical ingredients, and solid dosage formulations, as well as sale of radiopharmaceuticals through a network of 48 radio pharmacies in the United States. The Contract Research & Development Services segment provides collaborative research services to pharmaceutical innovators. The Proprietary Novel Drugs segment develops therapies in the areas of oncology and auto-immune disorders. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is headquartered in Noida, India.

Jubilant Pharmova Limited

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 29, 2024 7:29 PM	8032348d
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Sep 29, 2024 7:29 PM	c9fa84c3
crunchbase trigger	general	Nov 11, 2024 10:30 AM	6c0b69b6
crunchbase profile	general	Nov 12, 2024 8:54 AM	988b7ff9
li profile	general
translate crunchbase fundingrounds	general	Nov 12, 2024 9:06 AM	1a2e2463
peers	general	Sep 29, 2024 7:29 PM	237fd142
news basic	general	Sep 29, 2024 7:29 PM	9ff893db
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:JUBILANTPHARMOVA

Jubilant Pharmova

Last Close

1,130.35

22/11 10:00

Market Cap

115.38B

Beta: -

Volume Today

76.01K

Avg: -